RxDoctor Payments Data

Mariyam Cherry, MD

Internal Medicine · Lufkin, TXNPI 1750726550

Payments from drug & device makers

$1,446in general payments, 2019–2025

Across 74 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$648
  • Acadia Pharmaceuticals Inc$417
  • Teva Pharmaceuticals USA, Inc.$167
  • Jazz Pharmaceuticals Inc.$107
  • Abbott$51
  • Greenwich Biosciences, Inc.$35
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$1,446100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,446 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$155,592
Medicare patients
279
Services billed
1,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$91,289
MounjaroTirzepatide70$74,187
JardianceEmpagliflozin34$27,994
EliquisApixaban35$26,979
TrulicityDulaglutide13$25,140
Breo ElliptaFluticasone/Vilanterol49$19,653
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$17,545
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,894
MyrbetriqMirabegron31$13,455
Praluent PenAlirocumab18$8,287
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$7,888
Levothyroxine Sodium415$4,870
Losartan Potassium367$4,312
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,189
JanumetSitagliptin Phos/Metformin Hcl11$2,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$648$1,55544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →